Skip to content
Triangle logo TriangleGet started
← Back to this collection

LABELS · 9fdbd924-74fd-4b07-882c-d7e11b1a4642

SOLU-MEDROL

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date
2026-06-25
Captured
2026-09-09T23:37:54.830918+00:00
Current indication reconciliation
Not reconciled

Indications and usage: exact source text

  1. INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
Full extracted label fields
application numbers
  1. NDA011856
boxed warning exact
    brand names
    1. SOLU-MEDROL
    current indication status
    not_reconciled
    dailymed set url
    https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=7271310c-7764-4812-aa30-a5e90987c7a9
    generic names
    1. METHYLPREDNISOLONE SODIUM SUCCINATE
    id
    9fdbd924-74fd-4b07-882c-d7e11b1a4642
    indications and usage exact
    1. INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
    indications and usage tables exact
      is original packager
      1. true
      manufacturer names
      1. Pharmacia & Upjohn Company LLC
      matched search terms
      1. cancer
      2. lymphomas
      3. tumor
      package ndcs
      1. 0009-0698-02
      2. 0009-0039-05
      3. 0009-0039-06
      4. 0009-0047-03
      5. 0009-0047-04
      product ndcs
      1. 0009-0039
      2. 0009-0698
      3. 0009-0047
      product types
      1. HUMAN PRESCRIPTION DRUG
      recent major changes exact
        record type
        complete_spl_indications_section_candidate
        routes
        1. INTRAMUSCULAR
        2. INTRAVENOUS
        rxcuis
        1. 207191
        2. 207193
        3. 311659
        4. 314099
        5. 1743704
        6. 1743707
        source batch
        file
        /private/tmp/cancer-full-research/indications/raw/labels-00500.json
        meta
        disclaimer
        Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
        last updated
        2026-09-09
        results
        limit
        100
        skip
        500
        total
        830
        sha256
        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
        url
        https://api.fda.gov/drug/label.json?search=%28indications_and_usage%3Acancer+OR+indications_and_usage%3Acarcinoma+OR+indications_and_usage%3Acarcinomas+OR+indications_and_usage%3Alymphoma+OR+indications_and_usage%3Alymphomas+OR+indications_and_usage%3Aleukemia+OR+indications_and_usage%3Aleukaemia+OR+indications_and_usage%3Asarcoma+OR+indications_and_usage%3Asarcomas+OR+indications_and_usage%3Amelanoma+OR+indications_and_usage%3Amyeloma+OR+indications_and_usage%3Atumor+OR+indications_and_usage%3Atumors+OR+indications_and_usage%3Atumour+OR+indications_and_usage%3Atumours+OR+indications_and_usage%3Aneoplasm+OR+indications_and_usage%3Aneoplasms+OR+indications_and_usage%3Amalignant+OR+indications_and_usage%3Amalignancy+OR+indications_and_usage%3Amyelodysplastic+OR+indications_and_usage%3Amyelofibrosis+OR+indications_and_usage%3Amastocytosis+OR+indications_and_usage%3Aglioma+OR+indications_and_usage%3Aglioblastoma+OR+indications_and_usage%3Aneuroblastoma+OR+indications_and_usage%3Aretinoblastoma+OR+indications_and_usage%3Apheochromocytoma+OR+indications_and_usage%3Aparaganglioma+OR+indications_and_usage%3Amyeloproliferative+OR+indications_and_usage%3Awaldenstrom+OR+indications_and_usage%3Apolycythemia+OR+indications_and_usage%3Athrombocythemia+OR+indications_and_usage%3Adesmoid+OR+indications_and_usage%3Aneurofibromatosis+OR+indications_and_usage%3Ahistiocytosis%29+AND+%28openfda.application_number%3ANDA%2A+OR+openfda.application_number%3ABLA%2A%29&limit=100&skip=500&sort=id%3Aasc
        source url
        https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
        spl effective date
        2026-06-25
        spl effective time
        20260625
        spl set id
        7271310c-7764-4812-aa30-a5e90987c7a9
        spl version
        12
        substance names
        1. METHYLPREDNISOLONE SODIUM SUCCINATE
        uniis
        1. LEC9GKY20K
        verification flags
        1. oncology_keyword_candidate_not_clinically_classified
        2. spl_text_not_verified_identical_to_latest_approved_label
        3. individual_indications_not_split_or_reconciled
        Drugs@FDA application source records
        1. application number
          NDA011856
          payload
          all indexed label documents
          1. Appl No
            011856
            Application Docs Date
            2011-10-25 00:00:00
            Application Docs ID
            10784
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            104
            Submission Type
            SUPPL
          2. Appl No
            011856
            Application Docs Date
            2011-10-25 00:00:00
            Application Docs ID
            33061
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            103
            Submission Type
            SUPPL
          3. Appl No
            011856
            Application Docs Date
            2010-07-01 00:00:00
            Application Docs ID
            33062
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            107
            Submission Type
            SUPPL
          4. Appl No
            011856
            Application Docs Date
            2014-07-09 00:00:00
            Application Docs ID
            33063
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            123
            Submission Type
            SUPPL
          5. Appl No
            011856
            Application Docs Date
            2016-09-09 00:00:00
            Application Docs ID
            45262
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            124
            Submission Type
            SUPPL
          6. Appl No
            011856
            Application Docs Date
            2016-09-09 00:00:00
            Application Docs ID
            45263
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            126
            Submission Type
            SUPPL
          7. Appl No
            011856
            Application Docs Date
            2018-04-01 00:00:00
            Application Docs ID
            53571
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            131
            Submission Type
            SUPPL
          8. Appl No
            011856
            Application Docs Date
            2018-07-25 00:00:00
            Application Docs ID
            54963
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            133
            Submission Type
            SUPPL
          9. Appl No
            011856
            Application Docs Date
            2021-06-04 00:00:00
            Application Docs ID
            67701
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            136
            Submission Type
            SUPPL
          10. Appl No
            011856
            Application Docs Date
            2021-11-29 00:00:00
            Application Docs ID
            69419
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            139
            Submission Type
            SUPPL
          11. Appl No
            011856
            Application Docs Date
            2023-12-21 00:00:00
            Application Docs ID
            77105
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            141
            Submission Type
            SUPPL
          12. Appl No
            011856
            Application Docs Date
            2024-06-06 00:00:00
            Application Docs ID
            78675
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            144
            Submission Type
            SUPPL
          all submission records
          1. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            144
            Submission Status
            AP
            Submission Status Date
            2024-06-05 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          2. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            143
            Submission Status
            AP
            Submission Status Date
            2025-11-04 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          3. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            141
            Submission Status
            AP
            Submission Status Date
            2023-12-20 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          4. Appl No
            011856
            Review Priority
            N/A
            Submission Class Code ID
            4
            Submission No
            139
            Submission Status
            AP
            Submission Status Date
            2021-10-27 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          5. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            136
            Submission Status
            AP
            Submission Status Date
            2021-05-27 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          6. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            133
            Submission Status
            AP
            Submission Status Date
            2018-07-24 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          7. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            131
            Submission Status
            AP
            Submission Status Date
            2018-03-28 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          8. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            4
            Submission No
            127
            Submission Status
            AP
            Submission Status Date
            2015-08-06 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          9. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            126
            Submission Status
            AP
            Submission Status Date
            2016-09-08 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          10. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            124
            Submission Status
            AP
            Submission Status Date
            2016-09-08 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          11. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            3
            Submission No
            123
            Submission Status
            AP
            Submission Status Date
            2014-07-03 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          12. Appl No
            011856
            Review Priority
            STANDARD
            Submission Class Code ID
            4
            Submission No
            122
            Submission Status
            AP
            Submission Status Date
            2014-06-09 00:00:00
            Submission Type
            SUPPL
            Submissions Public Notes
          application number
          NDA011856
          approval interpretation
          Application linkage and approved submission are not indication-level current approval verification
          current indication status
          not_reconciled
          has approved submission record
          true
          latest approved submission date
          2025-11-04
          latest label selection rule
          max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
          latest posted label documents
          1. Appl No
            011856
            Application Docs Date
            2025-11-07 00:00:00
            Application Docs ID
            84121
            Application Docs Title
            0
            Application Docs Type ID
            2
            Submission No
            143
            Submission Type
            SUPPL
          official application record
          Appl No
          011856
          Appl Public Notes
          Appl Type
          NDA
          Sponsor Name
          PHARMACIA AND UPJOHN
          openfda application present
          true
          products
          1. Active Ingredient
            METHYLPREDNISOLONE SODIUM SUCCINATE
            Appl No
            011856
            Drug Name
            SOLU-MEDROL
            Form
            INJECTABLE;INJECTION
            Product No
            003
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 40MG BASE/VIAL
            marketing status
            1. Prescription
          2. Active Ingredient
            METHYLPREDNISOLONE SODIUM SUCCINATE
            Appl No
            011856
            Drug Name
            SOLU-MEDROL
            Form
            INJECTABLE;INJECTION
            Product No
            004
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 125MG BASE/VIAL
            marketing status
            1. Prescription
          3. Active Ingredient
            METHYLPREDNISOLONE SODIUM SUCCINATE
            Appl No
            011856
            Drug Name
            SOLU-MEDROL
            Form
            INJECTABLE;INJECTION
            Product No
            005
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 500MG BASE/VIAL
            marketing status
            1. Prescription
          4. Active Ingredient
            METHYLPREDNISOLONE SODIUM SUCCINATE
            Appl No
            011856
            Drug Name
            SOLU-MEDROL
            Form
            INJECTABLE;INJECTION
            Product No
            006
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 1GM BASE/VIAL
            marketing status
            1. Prescription
          5. Active Ingredient
            METHYLPREDNISOLONE SODIUM SUCCINATE
            Appl No
            011856
            Drug Name
            SOLU-MEDROL
            Form
            INJECTABLE;INJECTION
            Product No
            007
            Reference Drug
            1
            Reference Standard
            1
            Strength
            EQ 2GM BASE/VIAL
            marketing status
            1. Prescription

        Source passages and status connections

        Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

        Passage 1 · positive indication candidate
        application numbers
        1. NDA011856
        brand names
        1. SOLU-MEDROL
        classification reasons
        1. explicit_positive_indication_predicate
        2. no_tumor_directed_keyword_in_positive_statement
        clinical review status
        pending
        content role
        positive_indication_candidate
        context span
        end
        739
        end exclusive
        true
        exact text
        INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary
        label id
        9fdbd924-74fd-4b07-882c-d7e11b1a4642
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
        start
        0
        current approval status
        not_reconciled
        duplicate text group
        dup-696d6a9bc1503354dc11
        extraction review status
        automated_candidate_pending_source_review
        generic names
        1. METHYLPREDNISOLONE SODIUM SUCCINATE
        id
        ind-span-c17bb3471d288e7c05a1
        label id
        9fdbd924-74fd-4b07-882c-d7e11b1a4642
        positive predicate support span
        end
        274
        end exclusive
        true
        exact text
        is indicated
        label id
        9fdbd924-74fd-4b07-882c-d7e11b1a4642
        offset unit
        unicode_code_points
        source array index
        0
        source field
        indications_and_usage_exact
        source text sha256
        08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
        start
        262
        qualifier mentions
          regulatory links
            schema version
            0.1.0
            source batch sha256
            424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
            source defined aliases
              source span
              end
              539
              end exclusive
              true
              exact text
              INDICATIONS AND USAGE When oral therapy is not feasible, and the strength, dosage form, and route of administration of the drug reasonably lend the preparation to the treatment of the condition, the intravenous or intramuscular use of SOLU-MEDROL Sterile Powder is indicated as follows: Allergic states : Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions.
              label id
              9fdbd924-74fd-4b07-882c-d7e11b1a4642
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
              start
              0
              source url
              https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
              spl effective date
              2026-06-25
              spl set id
              7271310c-7764-4812-aa30-a5e90987c7a9
              spl version
              12
              structured fields status
              not_extracted_no_values_inferred_from_mentions
              structured indication
              age
              Source null
              approval pathway
              Source null
              biomarker and test
              Source null
              disease stage
              Source null
              limitations
              Source null
              line
              Source null
              prior therapy
              Source null
              regimen
              Source null
              tumor histology
              Source null
              use intent
              non_oncology_or_unclear_candidate
              Passage 2 · unclassified context
              application numbers
              1. NDA011856
              brand names
              1. SOLU-MEDROL
              classification reasons
              1. no_unambiguous_positive_indication_predicate
              clinical review status
              pending
              content role
              unclassified_context
              context span
              end
              908
              end exclusive
              true
              exact text
              allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, serum sickness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where
              label id
              9fdbd924-74fd-4b07-882c-d7e11b1a4642
              offset unit
              unicode_code_points
              source array index
              0
              source field
              indications_and_usage_exact
              source text sha256
              08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
              start
              340
              current approval status
              not_reconciled
              duplicate text group
              dup-6a72687dcd024eafe22a
              extraction review status
              automated_candidate_pending_source_review
              generic names
              1. METHYLPREDNISOLONE SODIUM SUCCINATE
              id
              ind-span-35248d765f25c6cb6eff
              label id
              9fdbd924-74fd-4b07-882c-d7e11b1a4642
              positive predicate support span
              Source null
              qualifier mentions
                regulatory links
                  schema version
                  0.1.0
                  source batch sha256
                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                  source defined aliases
                    source span
                    end
                    708
                    end exclusive
                    true
                    exact text
                    Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome).
                    label id
                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                    start
                    540
                    source url
                    https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                    spl effective date
                    2026-06-25
                    spl set id
                    7271310c-7764-4812-aa30-a5e90987c7a9
                    spl version
                    12
                    structured fields status
                    not_extracted_no_values_inferred_from_mentions
                    structured indication
                    age
                    Source null
                    approval pathway
                    Source null
                    biomarker and test
                    Source null
                    disease stage
                    Source null
                    limitations
                    Source null
                    line
                    Source null
                    prior therapy
                    Source null
                    regimen
                    Source null
                    tumor histology
                    Source null
                    use intent
                    unclear
                    Passage 3 · unclassified context
                    application numbers
                    1. NDA011856
                    brand names
                    1. SOLU-MEDROL
                    classification reasons
                    1. no_unambiguous_positive_indication_predicate
                    clinical review status
                    pending
                    content role
                    unclassified_context
                    context span
                    end
                    1293
                    end exclusive
                    true
                    exact text
                    ckness, transfusion reactions. Dermatologic diseases : Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) he
                    label id
                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                    offset unit
                    unicode_code_points
                    source array index
                    0
                    source field
                    indications_and_usage_exact
                    source text sha256
                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                    start
                    509
                    current approval status
                    not_reconciled
                    duplicate text group
                    dup-f75c42fe48e37fe308c2
                    extraction review status
                    automated_candidate_pending_source_review
                    generic names
                    1. METHYLPREDNISOLONE SODIUM SUCCINATE
                    id
                    ind-span-ff83896401892658dca7
                    label id
                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                    positive predicate support span
                    Source null
                    qualifier mentions
                      regulatory links
                        schema version
                        0.1.0
                        source batch sha256
                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                        source defined aliases
                          source span
                          end
                          1093
                          end exclusive
                          true
                          exact text
                          Endocrine disorders : Primary or secondary adrenocortical insufficiency (hydrocortisone or cortisone is the drug of choice; synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis.
                          label id
                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                          start
                          709
                          source url
                          https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                          spl effective date
                          2026-06-25
                          spl set id
                          7271310c-7764-4812-aa30-a5e90987c7a9
                          spl version
                          12
                          structured fields status
                          not_extracted_no_values_inferred_from_mentions
                          structured indication
                          age
                          Source null
                          approval pathway
                          Source null
                          biomarker and test
                          Source null
                          disease stage
                          Source null
                          limitations
                          Source null
                          line
                          Source null
                          prior therapy
                          Source null
                          regimen
                          Source null
                          tumor histology
                          Source null
                          use intent
                          unclear
                          Passage 4 · unclassified context
                          application numbers
                          1. NDA011856
                          brand names
                          1. SOLU-MEDROL
                          classification reasons
                          1. no_unambiguous_positive_indication_predicate
                          clinical review status
                          pending
                          content role
                          unclassified_context
                          context span
                          end
                          1444
                          end exclusive
                          true
                          exact text
                          ticoids where applicable; in infancy, mineralocorticoid supplementation is of particular importance), congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous adminis
                          label id
                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                          offset unit
                          unicode_code_points
                          source array index
                          0
                          source field
                          indications_and_usage_exact
                          source text sha256
                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                          start
                          894
                          current approval status
                          not_reconciled
                          duplicate text group
                          dup-0efe788c13f59b2ad7f2
                          extraction review status
                          automated_candidate_pending_source_review
                          generic names
                          1. METHYLPREDNISOLONE SODIUM SUCCINATE
                          id
                          ind-span-c8587e3e93a086f5a509
                          label id
                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                          positive predicate support span
                          Source null
                          qualifier mentions
                            regulatory links
                              schema version
                              0.1.0
                              source batch sha256
                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                              source defined aliases
                                source span
                                end
                                1244
                                end exclusive
                                true
                                exact text
                                Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis.
                                label id
                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                start
                                1094
                                source url
                                https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                spl effective date
                                2026-06-25
                                spl set id
                                7271310c-7764-4812-aa30-a5e90987c7a9
                                spl version
                                12
                                structured fields status
                                not_extracted_no_values_inferred_from_mentions
                                structured indication
                                age
                                Source null
                                approval pathway
                                Source null
                                biomarker and test
                                Source null
                                disease stage
                                Source null
                                limitations
                                Source null
                                line
                                Source null
                                prior therapy
                                Source null
                                regimen
                                Source null
                                tumor histology
                                Source null
                                use intent
                                unclear
                                Passage 5 · risk or warning
                                application numbers
                                1. NDA011856
                                brand names
                                1. SOLU-MEDROL
                                classification reasons
                                1. risk_or_warning_words_without_positive_predicate
                                clinical review status
                                pending
                                content role
                                risk_or_warning
                                context span
                                end
                                1776
                                end exclusive
                                true
                                exact text
                                ociated with cancer, nonsuppurative thyroiditis. Gastrointestinal diseases : To tide the patient over a critical period of the disease in regional enteritis (systemic therapy) and ulcerative colitis. Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemot
                                label id
                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                offset unit
                                unicode_code_points
                                source array index
                                0
                                source field
                                indications_and_usage_exact
                                source text sha256
                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                start
                                1045
                                current approval status
                                not_reconciled
                                duplicate text group
                                dup-6b291546c1be8f268448
                                extraction review status
                                automated_candidate_pending_source_review
                                generic names
                                1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                id
                                ind-span-0f887223ff73443a0b70
                                label id
                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                positive predicate support span
                                Source null
                                qualifier mentions
                                1. context exact
                                  nd-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administrat
                                  kind
                                  age
                                  polarity
                                  not_inferred
                                  span
                                  end
                                  1423
                                  end exclusive
                                  true
                                  exact text
                                  adults
                                  label id
                                  9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                  offset unit
                                  unicode_code_points
                                  source array index
                                  0
                                  source field
                                  indications_and_usage_exact
                                  source text sha256
                                  08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                  start
                                  1417
                                regulatory links
                                  schema version
                                  0.1.0
                                  source batch sha256
                                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                  source defined aliases
                                    source span
                                    end
                                    1576
                                    end exclusive
                                    true
                                    exact text
                                    Hematologic disorders : Acquired (autoimmune) hemolytic anemia, congenital (erythroid) hypoplastic anemia (Diamond-Blackfan anemia), idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia.
                                    label id
                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                    start
                                    1245
                                    source url
                                    https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                    spl effective date
                                    2026-06-25
                                    spl set id
                                    7271310c-7764-4812-aa30-a5e90987c7a9
                                    spl version
                                    12
                                    structured fields status
                                    not_extracted_no_values_inferred_from_mentions
                                    structured indication
                                    age
                                    Source null
                                    approval pathway
                                    Source null
                                    biomarker and test
                                    Source null
                                    disease stage
                                    Source null
                                    limitations
                                    Source null
                                    line
                                    Source null
                                    prior therapy
                                    Source null
                                    regimen
                                    Source null
                                    tumor histology
                                    Source null
                                    use intent
                                    not_applicable
                                    Passage 6 · unclassified context
                                    application numbers
                                    1. NDA011856
                                    brand names
                                    1. SOLU-MEDROL
                                    classification reasons
                                    1. no_unambiguous_positive_indication_predicate
                                    clinical review status
                                    pending
                                    content role
                                    unclassified_context
                                    context span
                                    end
                                    1983
                                    end exclusive
                                    true
                                    exact text
                                    idiopathic thrombocytopenic purpura in adults (intravenous administration only; intramuscular administration is contraindicated), pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain
                                    label id
                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                    offset unit
                                    unicode_code_points
                                    source array index
                                    0
                                    source field
                                    indications_and_usage_exact
                                    source text sha256
                                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                    start
                                    1377
                                    current approval status
                                    not_reconciled
                                    duplicate text group
                                    dup-97f6274cb5029e5ee76c
                                    extraction review status
                                    automated_candidate_pending_source_review
                                    generic names
                                    1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                    id
                                    ind-span-34bf3cb5c4ddb73a6fab
                                    label id
                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                    positive predicate support span
                                    Source null
                                    qualifier mentions
                                      regulatory links
                                        schema version
                                        0.1.0
                                        source batch sha256
                                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                        source defined aliases
                                          source span
                                          end
                                          1783
                                          end exclusive
                                          true
                                          exact text
                                          Miscellaneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy.
                                          label id
                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                          start
                                          1577
                                          source url
                                          https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                          spl effective date
                                          2026-06-25
                                          spl set id
                                          7271310c-7764-4812-aa30-a5e90987c7a9
                                          spl version
                                          12
                                          structured fields status
                                          not_extracted_no_values_inferred_from_mentions
                                          structured indication
                                          age
                                          Source null
                                          approval pathway
                                          Source null
                                          biomarker and test
                                          Source null
                                          disease stage
                                          Source null
                                          limitations
                                          Source null
                                          line
                                          Source null
                                          prior therapy
                                          Source null
                                          regimen
                                          Source null
                                          tumor histology
                                          Source null
                                          use intent
                                          unclear
                                          Passage 7 · unclassified context
                                          application numbers
                                          1. NDA011856
                                          brand names
                                          1. SOLU-MEDROL
                                          classification reasons
                                          1. no_unambiguous_positive_indication_predicate
                                          clinical review status
                                          pending
                                          content role
                                          unclassified_context
                                          context span
                                          end
                                          2063
                                          end exclusive
                                          true
                                          exact text
                                          aneous : Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and
                                          label id
                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                          offset unit
                                          unicode_code_points
                                          source array index
                                          0
                                          source field
                                          indications_and_usage_exact
                                          source text sha256
                                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                          start
                                          1584
                                          current approval status
                                          not_reconciled
                                          duplicate text group
                                          dup-509483ea066898c8857a
                                          extraction review status
                                          automated_candidate_pending_source_review
                                          generic names
                                          1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                          id
                                          ind-span-c4af9d81ae46c58f5b74
                                          label id
                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                          positive predicate support span
                                          Source null
                                          qualifier mentions
                                            regulatory links
                                              schema version
                                              0.1.0
                                              source batch sha256
                                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                              source defined aliases
                                                source span
                                                end
                                                1863
                                                end exclusive
                                                true
                                                exact text
                                                Neoplastic diseases : For the palliative management of leukemias and lymphomas.
                                                label id
                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                start
                                                1784
                                                source url
                                                https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                spl effective date
                                                2026-06-25
                                                spl set id
                                                7271310c-7764-4812-aa30-a5e90987c7a9
                                                spl version
                                                12
                                                structured fields status
                                                not_extracted_no_values_inferred_from_mentions
                                                structured indication
                                                age
                                                Source null
                                                approval pathway
                                                Source null
                                                biomarker and test
                                                Source null
                                                disease stage
                                                Source null
                                                limitations
                                                Source null
                                                line
                                                Source null
                                                prior therapy
                                                Source null
                                                regimen
                                                Source null
                                                tumor histology
                                                Source null
                                                use intent
                                                unclear
                                                Passage 8 · unclassified context
                                                application numbers
                                                1. NDA011856
                                                brand names
                                                1. SOLU-MEDROL
                                                classification reasons
                                                1. no_unambiguous_positive_indication_predicate
                                                clinical review status
                                                pending
                                                content role
                                                unclassified_context
                                                context span
                                                end
                                                2204
                                                end exclusive
                                                true
                                                exact text
                                                ngitis with subarachnoid block or impending block when used concurrently with appropriate antituberculous chemotherapy. Neoplastic diseases : For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in id
                                                label id
                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                offset unit
                                                unicode_code_points
                                                source array index
                                                0
                                                source field
                                                indications_and_usage_exact
                                                source text sha256
                                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                start
                                                1664
                                                current approval status
                                                not_reconciled
                                                duplicate text group
                                                dup-53a30b50a238f8db1c5e
                                                extraction review status
                                                automated_candidate_pending_source_review
                                                generic names
                                                1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                id
                                                ind-span-b0b8883e6689891ab5ff
                                                label id
                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                positive predicate support span
                                                Source null
                                                qualifier mentions
                                                1. context exact
                                                  ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
                                                  kind
                                                  biomarker
                                                  polarity
                                                  not_inferred
                                                  span
                                                  end
                                                  1988
                                                  end exclusive
                                                  true
                                                  exact text
                                                  metastatic brain tumor
                                                  label id
                                                  9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                  start
                                                  1966
                                                2. context exact
                                                  ltiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
                                                  kind
                                                  stage_or_setting
                                                  polarity
                                                  not_inferred
                                                  span
                                                  end
                                                  1988
                                                  end exclusive
                                                  true
                                                  exact text
                                                  metastatic brain tumor
                                                  label id
                                                  9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                  offset unit
                                                  unicode_code_points
                                                  source array index
                                                  0
                                                  source field
                                                  indications_and_usage_exact
                                                  source text sha256
                                                  08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                  start
                                                  1966
                                                regulatory links
                                                  schema version
                                                  0.1.0
                                                  source batch sha256
                                                  424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                  source defined aliases
                                                    source span
                                                    end
                                                    2004
                                                    end exclusive
                                                    true
                                                    exact text
                                                    Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy.
                                                    label id
                                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                    start
                                                    1864
                                                    source url
                                                    https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                    spl effective date
                                                    2026-06-25
                                                    spl set id
                                                    7271310c-7764-4812-aa30-a5e90987c7a9
                                                    spl version
                                                    12
                                                    structured fields status
                                                    not_extracted_no_values_inferred_from_mentions
                                                    structured indication
                                                    age
                                                    Source null
                                                    approval pathway
                                                    Source null
                                                    biomarker and test
                                                    Source null
                                                    disease stage
                                                    Source null
                                                    limitations
                                                    Source null
                                                    line
                                                    Source null
                                                    prior therapy
                                                    Source null
                                                    regimen
                                                    Source null
                                                    tumor histology
                                                    Source null
                                                    use intent
                                                    unclear
                                                    Passage 9 · unclassified context
                                                    application numbers
                                                    1. NDA011856
                                                    brand names
                                                    1. SOLU-MEDROL
                                                    classification reasons
                                                    1. no_unambiguous_positive_indication_predicate
                                                    clinical review status
                                                    pending
                                                    content role
                                                    unclassified_context
                                                    context span
                                                    end
                                                    2334
                                                    end exclusive
                                                    true
                                                    exact text
                                                    For the palliative management of leukemias and lymphomas. Nervous System : Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pu
                                                    label id
                                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                    offset unit
                                                    unicode_code_points
                                                    source array index
                                                    0
                                                    source field
                                                    indications_and_usage_exact
                                                    source text sha256
                                                    08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                    start
                                                    1805
                                                    current approval status
                                                    not_reconciled
                                                    duplicate text group
                                                    dup-a801c13a793507a86e4f
                                                    extraction review status
                                                    automated_candidate_pending_source_review
                                                    generic names
                                                    1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                    id
                                                    ind-span-c870e5a3d0dc6f47e97f
                                                    label id
                                                    9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                    positive predicate support span
                                                    Source null
                                                    qualifier mentions
                                                      regulatory links
                                                        schema version
                                                        0.1.0
                                                        source batch sha256
                                                        424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                        source defined aliases
                                                          source span
                                                          end
                                                          2134
                                                          end exclusive
                                                          true
                                                          exact text
                                                          Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids.
                                                          label id
                                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                          start
                                                          2005
                                                          source url
                                                          https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                          spl effective date
                                                          2026-06-25
                                                          spl set id
                                                          7271310c-7764-4812-aa30-a5e90987c7a9
                                                          spl version
                                                          12
                                                          structured fields status
                                                          not_extracted_no_values_inferred_from_mentions
                                                          structured indication
                                                          age
                                                          Source null
                                                          approval pathway
                                                          Source null
                                                          biomarker and test
                                                          Source null
                                                          disease stage
                                                          Source null
                                                          limitations
                                                          Source null
                                                          line
                                                          Source null
                                                          prior therapy
                                                          Source null
                                                          regimen
                                                          Source null
                                                          tumor histology
                                                          Source null
                                                          use intent
                                                          unclear
                                                          Passage 10 · unclassified context
                                                          application numbers
                                                          1. NDA011856
                                                          brand names
                                                          1. SOLU-MEDROL
                                                          classification reasons
                                                          1. no_unambiguous_positive_indication_predicate
                                                          clinical review status
                                                          pending
                                                          content role
                                                          unclassified_context
                                                          context span
                                                          end
                                                          2467
                                                          end exclusive
                                                          true
                                                          exact text
                                                          ema associated with primary or metastatic brain tumor, or craniotomy. Ophthalmic diseases : Sympathetic ophthalmia, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, sympto
                                                          label id
                                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                          offset unit
                                                          unicode_code_points
                                                          source array index
                                                          0
                                                          source field
                                                          indications_and_usage_exact
                                                          source text sha256
                                                          08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                          start
                                                          1935
                                                          current approval status
                                                          not_reconciled
                                                          duplicate text group
                                                          dup-4d667d53759e7d1af2bd
                                                          extraction review status
                                                          automated_candidate_pending_source_review
                                                          generic names
                                                          1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                          id
                                                          ind-span-420431cc5a377dbaf23c
                                                          label id
                                                          9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                          positive predicate support span
                                                          Source null
                                                          qualifier mentions
                                                            regulatory links
                                                              schema version
                                                              0.1.0
                                                              source batch sha256
                                                              424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                              source defined aliases
                                                                source span
                                                                end
                                                                2267
                                                                end exclusive
                                                                true
                                                                exact text
                                                                Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus.
                                                                label id
                                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                start
                                                                2135
                                                                source url
                                                                https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                                spl effective date
                                                                2026-06-25
                                                                spl set id
                                                                7271310c-7764-4812-aa30-a5e90987c7a9
                                                                spl version
                                                                12
                                                                structured fields status
                                                                not_extracted_no_values_inferred_from_mentions
                                                                structured indication
                                                                age
                                                                Source null
                                                                approval pathway
                                                                Source null
                                                                biomarker and test
                                                                Source null
                                                                disease stage
                                                                Source null
                                                                limitations
                                                                Source null
                                                                line
                                                                Source null
                                                                prior therapy
                                                                Source null
                                                                regimen
                                                                Source null
                                                                tumor histology
                                                                Source null
                                                                use intent
                                                                unclear
                                                                Passage 11 · unclassified context
                                                                application numbers
                                                                1. NDA011856
                                                                brand names
                                                                1. SOLU-MEDROL
                                                                classification reasons
                                                                1. no_unambiguous_positive_indication_predicate
                                                                clinical review status
                                                                pending
                                                                content role
                                                                unclassified_context
                                                                context span
                                                                end
                                                                2685
                                                                end exclusive
                                                                true
                                                                exact text
                                                                r inflammatory conditions unresponsive to topical corticosteroids. Renal diseases : To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing sp
                                                                label id
                                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                offset unit
                                                                unicode_code_points
                                                                source array index
                                                                0
                                                                source field
                                                                indications_and_usage_exact
                                                                source text sha256
                                                                08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                start
                                                                2068
                                                                current approval status
                                                                not_reconciled
                                                                duplicate text group
                                                                dup-878982f27377ff963d18
                                                                extraction review status
                                                                automated_candidate_pending_source_review
                                                                generic names
                                                                1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                                id
                                                                ind-span-5dfe95ccd5fe179401a3
                                                                label id
                                                                9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                positive predicate support span
                                                                Source null
                                                                qualifier mentions
                                                                  regulatory links
                                                                    schema version
                                                                    0.1.0
                                                                    source batch sha256
                                                                    424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                                    source defined aliases
                                                                      source span
                                                                      end
                                                                      2485
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      Respiratory diseases : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis.
                                                                      label id
                                                                      9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                      start
                                                                      2268
                                                                      source url
                                                                      https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                                      spl effective date
                                                                      2026-06-25
                                                                      spl set id
                                                                      7271310c-7764-4812-aa30-a5e90987c7a9
                                                                      spl version
                                                                      12
                                                                      structured fields status
                                                                      not_extracted_no_values_inferred_from_mentions
                                                                      structured indication
                                                                      age
                                                                      Source null
                                                                      approval pathway
                                                                      Source null
                                                                      biomarker and test
                                                                      Source null
                                                                      disease stage
                                                                      Source null
                                                                      limitations
                                                                      Source null
                                                                      line
                                                                      Source null
                                                                      prior therapy
                                                                      Source null
                                                                      regimen
                                                                      Source null
                                                                      tumor histology
                                                                      Source null
                                                                      use intent
                                                                      unclear
                                                                      Passage 12 · unclassified context
                                                                      application numbers
                                                                      1. NDA011856
                                                                      brand names
                                                                      1. SOLU-MEDROL
                                                                      classification reasons
                                                                      1. no_unambiguous_positive_indication_predicate
                                                                      clinical review status
                                                                      pending
                                                                      content role
                                                                      unclassified_context
                                                                      context span
                                                                      end
                                                                      2943
                                                                      end exclusive
                                                                      true
                                                                      exact text
                                                                      es : Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
                                                                      label id
                                                                      9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                      offset unit
                                                                      unicode_code_points
                                                                      source array index
                                                                      0
                                                                      source field
                                                                      indications_and_usage_exact
                                                                      source text sha256
                                                                      08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                      start
                                                                      2286
                                                                      current approval status
                                                                      not_reconciled
                                                                      duplicate text group
                                                                      dup-cffaf3cb2f4416cb4c34
                                                                      extraction review status
                                                                      automated_candidate_pending_source_review
                                                                      generic names
                                                                      1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                                      id
                                                                      ind-span-17337d4db56d95d19550
                                                                      label id
                                                                      9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                      positive predicate support span
                                                                      Source null
                                                                      qualifier mentions
                                                                        regulatory links
                                                                          schema version
                                                                          0.1.0
                                                                          source batch sha256
                                                                          424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                                          source defined aliases
                                                                            source span
                                                                            end
                                                                            2837
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            Rheumatic disorders : As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy).
                                                                            label id
                                                                            9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                            start
                                                                            2486
                                                                            source url
                                                                            https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                                            spl effective date
                                                                            2026-06-25
                                                                            spl set id
                                                                            7271310c-7764-4812-aa30-a5e90987c7a9
                                                                            spl version
                                                                            12
                                                                            structured fields status
                                                                            not_extracted_no_values_inferred_from_mentions
                                                                            structured indication
                                                                            age
                                                                            Source null
                                                                            approval pathway
                                                                            Source null
                                                                            biomarker and test
                                                                            Source null
                                                                            disease stage
                                                                            Source null
                                                                            limitations
                                                                            Source null
                                                                            line
                                                                            Source null
                                                                            prior therapy
                                                                            Source null
                                                                            regimen
                                                                            Source null
                                                                            tumor histology
                                                                            Source null
                                                                            use intent
                                                                            unclear
                                                                            Passage 13 · unclassified context
                                                                            application numbers
                                                                            1. NDA011856
                                                                            brand names
                                                                            1. SOLU-MEDROL
                                                                            classification reasons
                                                                            1. no_unambiguous_positive_indication_predicate
                                                                            clinical review status
                                                                            pending
                                                                            content role
                                                                            unclassified_context
                                                                            context span
                                                                            end
                                                                            2943
                                                                            end exclusive
                                                                            true
                                                                            exact text
                                                                            hritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
                                                                            label id
                                                                            9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                            offset unit
                                                                            unicode_code_points
                                                                            source array index
                                                                            0
                                                                            source field
                                                                            indications_and_usage_exact
                                                                            source text sha256
                                                                            08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                            start
                                                                            2638
                                                                            current approval status
                                                                            not_reconciled
                                                                            duplicate text group
                                                                            dup-037ba225b5e9f3edb50d
                                                                            extraction review status
                                                                            automated_candidate_pending_source_review
                                                                            generic names
                                                                            1. METHYLPREDNISOLONE SODIUM SUCCINATE
                                                                            id
                                                                            ind-span-231ae6559053bb4ee463
                                                                            label id
                                                                            9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                            positive predicate support span
                                                                            Source null
                                                                            qualifier mentions
                                                                              regulatory links
                                                                                schema version
                                                                                0.1.0
                                                                                source batch sha256
                                                                                424ccf5bc67db0a96ee2c35ed913dd5894642716182773d81ca19cdfb9ba32f3
                                                                                source defined aliases
                                                                                  source span
                                                                                  end
                                                                                  2943
                                                                                  end exclusive
                                                                                  true
                                                                                  exact text
                                                                                  For the treatment of dermatomyositis, temporal arteritis, polymyositis, and systemic lupus erythematosus.
                                                                                  label id
                                                                                  9fdbd924-74fd-4b07-882c-d7e11b1a4642
                                                                                  offset unit
                                                                                  unicode_code_points
                                                                                  source array index
                                                                                  0
                                                                                  source field
                                                                                  indications_and_usage_exact
                                                                                  source text sha256
                                                                                  08b4b3a42ee1f34b60c575f81bb93840d8cadad25312dcdb595a8fa14e9c10e9
                                                                                  start
                                                                                  2838
                                                                                  source url
                                                                                  https://api.fda.gov/drug/label.json?search=id%3A%229fdbd924-74fd-4b07-882c-d7e11b1a4642%22
                                                                                  spl effective date
                                                                                  2026-06-25
                                                                                  spl set id
                                                                                  7271310c-7764-4812-aa30-a5e90987c7a9
                                                                                  spl version
                                                                                  12
                                                                                  structured fields status
                                                                                  not_extracted_no_values_inferred_from_mentions
                                                                                  structured indication
                                                                                  age
                                                                                  Source null
                                                                                  approval pathway
                                                                                  Source null
                                                                                  biomarker and test
                                                                                  Source null
                                                                                  disease stage
                                                                                  Source null
                                                                                  limitations
                                                                                  Source null
                                                                                  line
                                                                                  Source null
                                                                                  prior therapy
                                                                                  Source null
                                                                                  regimen
                                                                                  Source null
                                                                                  tumor histology
                                                                                  Source null
                                                                                  use intent
                                                                                  unclear

                                                                                  Preserved source evidence · Not medical advice